Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACC-001 and QS-21 in Japanese Subjects With Alzheimer's Disease
NCT00752232Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2008
- Primary completion
- Jul 2012
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vanutide cridificar in Alzheimer's disease (AD), sponsored by Pfizer. Started Dec 2008; status: completed.
02
Drugs
vanutide cridificar
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00752232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00752232.